Czech Republic
Include All CSL Behring Country Sites

Company History

Please note that the following describes the history of a global organisation and not all the products or their indications are licensed for use or marketed in the UK.

CSL Behring and our parent company, CSL Limited, continue to build on a long legacy of innovation in patient care. CSL Behring traces its beginnings to the 1904 founding of Behringwerke, a company established by Emil von Behring, the first recipient of the Nobel Prize in Medicine. In 1916 our parent company, CSL Limited, was founded to supply vaccines to the people of Australia. During the 20th century, leading companies came together to form CSL Behring. For more than 60 years, we have specialised in providing plasma therapies to improve the quality of life for people with rare and serious diseases worldwide.

Our biotherapies are used to treat immune deficiency disorders, hereditary angioedema, haemophilia, von Willebrand disease and other bleeding disorders. Other products are used for the prevention of haemolytic diseases in the newborn.

CSL Behring. Providing biotherapies for life for more than a century.

1901 Emil von Behring receives first Nobel Prize in Medicine
German doctor Emil von Behring receives the first Nobel Prize in Physiology and Medicine for his work on serum therapies. Von Behring’s pioneering work results in the modern methods of immunisation that have largely eradicated diptheria worlwide.
1904 Emil von Behring creates Behringwerke
Emil von Behring creates Behringwerke (a predecessor company) to produce sera and vaccines to combat infectious diseases.
1913 Anti-infectious agents
Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
1940 WWII: Largest supplier of albumin for U.S. military
Armour (a predecessor company) becomes the largest supplier of human albumin for the U.S. military during World War II.
1946 Europe’s first human plasma fractionation
Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale.
1949 ZLB established
The Zentrallaboratorium Blutspendedienst (ZLB), a predecessor company, is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland.
1951 ZLB mandate to supply blood products
ZLB receives a mandate from the Swiss government to supply blood products through the Swiss Red Cross Blood Transfusion Service.
1951 Polio Immune Globulin
Armour Pharmaceuticals produced large quantities of polio immune globulin, a forerunner of the Salk polio vaccine, during the 1950s.
1954 First pasteurised plasma protein solution
ZLB produces the first pasteurised plasma protein solution.
1955 Researchers discover Alpha-1
Alpha-1 antitrypsin, a proteinase inhibitor, is discovered, purified and characterised for the first time by researchers of Behringwerke.
1962 New fractionation process provides better yield
Kistler and Nitschmann, researchers with ZLB, develop a new plasma fractionation method that provides significantly better yields of the valuable proteins isolated from human plasma.
1970 Japan’s first IVIg*
Behringwerke launches Gamma-Venin®, the first intravenous immune globulin (IVIg) product in Japan.
1979 Launch of first purified IVIg*
ZLB and Sandoz AG, Switzerland, launch Sandoglobulin®, the world’s first purified immunoglobulin product for intravenous infusion.
1981 Launch of first pasteurised factor VIII therapy
Behringwerke introduces Haemate® human plasma coagulation factor VIII/von Willebrand factor complex, first marketed in Europe for the treatment of patients with haemophilia A. It is the first pasteurised factor VIII product in the world.
1984 First IVIg approved in U.S.*
ZLB receives approval for polyvalent immunoglobulin - the first IVIg product to be approved in the United States.
1986 Humate-P® approved in U.S.*
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for the prevention and control of haemorrhagic episodes in patients with haemophilia A.
1988 First fibrin sealant launched in Japan*
Behringwerke launches Beriplast® P, the first fibrin sealant in Japan.
1990 Monoclate®-P launched*
Monoclate®-P, the second generation form of Monoclate Factor VIII using monoclonal antibody technology, adds pasteurisation as an additional viral removal step.
1992 Mononine® approved in U.S.
FDA approves Mononine®, a monoclonal antibody purified Factor IX product for treatment of haemophilia B. Mononine® was the first highly purified FIX in the U.S. market and is still the gold standard.
1993 Helixate® approved in U.S.
The FDA approves Helixate® recombinant coagulation factor VIII for the treatment of haemophilia A.
1996 Armour and Behringwerke become Centeon
Centeon (a predecessor company) is formed as 50/50 joint venture between Armour Pharmaceuticals and Behringwerke. At the time, Armour was owned by Rhone-Poulenc Rorer and Behringwerke was owned by Hoechst AG.
1996 Rhophylac®, world’s first liquid anti-D immunoglobulin,launched
Rhophylac® is launched as the world’s first liquid anti-D immunoglobulin for the prevention of haemolytic disease in newborns due to Rh factor incompatibility.
1998 €50 million plant modernisation
A major, 50 million Euro capital project is completed to modernise production facilities in Marburg, Germany.
1999 Centeon becomes Aventis Behring
Centeon changes its name to Aventis Behring when its parent companies Rhone-Poulenc Rorer (RPR) and Hoechst AG merge to become Aventis.
1999 First von Willebrand factor in U.S.*
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for treatment of von Willebrand disease, the most common hereditary bleeding disorder.
2000 New formulation of recombinant Factor VIII
Helixate® FS/ Helixate® NexGen recombinant coagulation factor VIII, formulated with sucrose for the treatment of haemophilia A, is approved by the FDA for use in U.S. and by the EMEA for use in 15 countries.
2000 ZLB Bioplasma established
CSL acquires ZLB Blood Transfusion Service (ZLB Zentrallaboratorium) from the Swiss Red Cross to establish ZLB Bioplasma (a predecessor company), headquartered in Bern, Switzerland.
2001 ZLB Plasma Services established
CSL acquires 47 plasma collection centres and laboratory facilities operated by Nabi Plasma Collection Centres (U.S.) and creates ZLB Plasma Services, now CSL Plasma.
2001 World’s largest plasma collection business
Aventis Behring acquires 42 plasma centres from Serologicals, forming the world’s largest plasma collection business.
2001 Foundation established
The company establishes a foundation for research and advancement of patient health—the only non-profit foundation dedicated exclusively to charitable, scientific and educational endeavours that benefit the bleeding disorders community.
2003 Carimune® NF launched in U.S.*
The company begins marketing Carimune® NF, the first nanofiltered human normal immunoglobulin for intravenous (IV) administration, in the United States.
2003 Zemaira® approved in U.S.*
FDA approves Zemaira® human Alpha-1 proteinase inhibitor for individuals with Alpha-1 proteinase inhibitor deficiency and clinical evidence of emphysema.
2003 Rhophylac® launches in UK
Rhophylac® human anti-D immunoglobulin launches in the UK.
2004 ZLB Behring established
CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring, today known as CSL Behring.
2004 EMEA approves Mononine®
The EMEA approves Mononine® human coagulation factor IX concentrate as the first product to treat haemophilia B patients undergoing surgery, exposed to trauma, or experiencing severe, spontaneous haemorrhage.
2004 Rhophylac® approved in U.S.
ZLB’s Rhophylac® human anti-D immunoglobulin is approved by the FDA.
2004 Sandoglobulin® NF Liquid launches in UK
Sandoglobulin® NF Liquid human normal immunoglobulin, IVIg launches in the UK.
2005 Mix2Vial introduced
Mix2Vial is introduced as an alternate transfer device, offering a new way to reconstitute products.
2005 Vivaglobin® approved in UK
Vivaglobin® human normal immunoglobulin, SCIg is licensed for use in the UK in adults and children who require antibody replacement due to primary immunodeficiency.
2006 Groundbreaking: state-of-the-art Ig plant
Construction begins on a new immunoglobulin manufacturing plant at the company’s Bern, Switzerland facility.
2006 State-of-the-art plant licensed by FDA
Highly automated facility in Kankakee, Illinois to allow for increased production of Zemaira®.
2006 Vivaglobin® first SCIg in U.S.*
FDA grants marketing approval for Vivaglobin® human normal immunoglobulin for subcutaneous administration. Vivaglobin is the first FDA-approved subcutaneous immunoglobulin treatment.
2006 Haemate P® 50% volume reduction in UK
Haemate P® human coagulation factor VIII/von Willebrand factor complex is now available in the UK featuring a smaller diluent - 50 percent less in all assay sizes, shortening infusion time and requiring less storage space.
2006 Cytogam® acquired*
Cytogam®, an IVIg enriched with antibodies against cytomegalovirus - the most common cause of life-threatening infection occurring in patients with solid organ transplants - is acquired by company.
2006 Two Ig formulations available in Canada*
With the approvals of Sandoglobulin® NF Liquid IVIg and Vivaglobin® subcutaneous Ig in Canada, the company now offers two formulations of immunoglobulin for people with primary immune deficiency.
2007 ZLB Behring becomes CSL Behring
As part of a global brand alignment, ZLB Behring changes its name to CSL Behring.
2007 Privigen® approved by FDA
FDA grants marketing approval for Privigen®, the first proline-stabilised intravenous immunoglobulin, IVIg, for treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura.
2007 Rhophylac® approved for ITP in U.S.
FDA approves Rhophylac® for additional indication - the treatment of immune thrombocytopenic purpura (ITP).
2008 Professor Heimberger research award established
CSL Behring establishes a research award to recognise the next generation of coagulation specialists. Award named in honor of the late Behringwerke employee and pioneering haemophilia specialist, Dr. Norbert Heimberger. While at Behringwerke, Dr. Heimberger discovered a novel method for plasma-protein pasteurisation.
2008 Mutual Recognition Procedure for Berinert® P completed
Berinert® P is approved for use in 20 additional countries in Europe. European countries to help people suffering from hereditary angioedema.
2008 Beriplex® launches in the UK
Beriplex® human prothrombin complex is licensed for use in the UK for the rapid reversal of oral anticoagulants.
2009 Orphan-drug exclusivity granted to Riastap®
FDA grants CSL Behring seven years of orphan-drug exclusivity for Riastap®, the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.
2009 New Ig Lab Plant approved in Bern, Switzerland
FDA, EMEA, Swissmedic and TGA approve new state-of-the-art immunoglobulin manufacturing plant at Bern, Switzerland manufacturing facility.
2009 CSL Plasma opens state-of-the-art laboratory
ZLB Plasma changes its name to CSL Plasma to align with its parent company, CSL Behring, and opens one of the world’s largest and most advanced plasma testing laboratories in Knoxville, TN.
2009 CSL Behring gives $2 million to WFH GAP Programme
To advance the diagnosis and treatment of haemophilia in developing countries, CSL Behring donates $2 million USD worth of coagulation factor to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) programme for a three-year period.
2009 NORD honors CSL Behring with rare disease award
National Organisation for Rare Disorders (NORD) recognises CSL Behring for developing and marketing Riastap®, the U.S.’s first and only treatment for acute bleeding episodes in patients with congenital fibrinogen deficiency, an extremely rare, potentially life-threatening bleeding disorder.
2009 CSL Behring receives Tell Award for Innovation
CSL Behring awarded the Swiss government’s Tell Award for the most significant innovative technology investment in 2008. This award recognises CSL Behring’s exceptional innovations in state-of-the-art manufacturing and novel protein therapies.
2009 Berinert®, first therapy for acute attacks of HAE in U.S.
FDA grants marketing approval for Berinert® C1-esterase inhibitor, the country’s first and only therapy for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE).
2009 Berinert® launches in the UK
CSL Behring launches Berinert® C1 esterase inhibitor for the treatment of acute episodes of hereditary angioedema type I and II.
2009 Privigen® launches in the UK
CSL Behring launches Privigen® human normal immunoglobulin, its latest intravenous immunoglobulin (IVIg) product in a 10% liquid preparation.
2010 Hizentra®, first and only 20 percent SCIg, approved by FDA
FDA grants marketing approval for Hizentra®, the first and only 20 percent subcutaneous immunoglobulin (SCIg). In the US, Hizentra is indicated for the treatment of patients with primary immune deficiency. Hizentra is also in registration in the EU and Switzerland. Stabilised with L-proline, Hizentra is ready to use; it requires no refrigeration throughout its 30-month shelf-life, offering patients and physicians convenience and portability.
2011 FDA approves Corifact, first and only FXIII concentrate approved in U.S.*
FDA grants marketing approval for Corifact for the treatment of congenital factor XIII (FXIII) deficiency. Congenital FXIII deficiency is a rare and potentially life-threatening bleeding disorder that affects an estimated 1 person in 2 million. Corifact is also available in 12 countries under the trade name Fibrogammin®.
2011 Riastap®▼ launches in the UK
CSL Behring launches Riastap® human fibrinogen, the first and only licensed fibrinogen concentrate in the UK.
2011 Hizentra®▼ launches in the UK
CSL Behring launches Hizentra® human normal immunoglobulin, SCIg, its latest subcutaneous product in 20% solution.
  CSL Behring continues to build on its legacy of innovation and patient care.

* Indicates product or indication not licensed for use or marketed in the UK.
No longer licensed or available in the UK.